Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A McDonald

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Expert Review of Cardiovascular Therapy|September 22, 2011
Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the betterSean Balmain, Michael A McDonald
Circulation|August 23, 2006
Angiotensin receptor blockers do not increase risk of myocardial infarctionRoss T Tsuyuki, Michael A McDonald
Academic Radiology|August 22, 2002
Multi-modal contrast agents: a first stepKenneth L Watkin, Michael A McDonald
Investigative Radiology|August 12, 2003
Small particulate gadolinium oxide and gadolinium oxide albumin microspheres as multimodal contrast and therapeutic agentsMichael A McDonald, Kenneth L Watkin
Current Opinion in Cardiology|March 12, 2009
Trying to succeed when the right ventricle failsMichael A McDonald, Heather J Ross
Advances in Applied Microbiology|October 22, 2018
Diversity-Function Relationships in Natural, Applied, and Engineered Microbial EcosystemsAndrew Free, Michael A McDonald, Eulyn Pagaling
Proceedings of Spie--The International Society for Optical Engineering|July 10, 2012
Protein Nanospheres: Synergistic Nanoplatform-Based Probes for Multimodality ImagingMichael A McDonald, Paul C Wang, Eliot L Siegel
The New England Journal of Medicine|January 15, 2010
Cardiac-resynchronization therapyJustin A Mariani, Michael A McDonald, Gary E Newton
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 24, 2012
Highly sensitized patients in cardiac transplantation: early outcomes from the Canadian Prioritized Organ Sharing ProgramSharon Chih, Heather J Ross, Michael A McDonald, et al.
Frontiers in Oncology|October 5, 2020
Phase 0 Radiopharmaceutical-Agent Clinical DevelopmentCharles A Kunos, Larry V Rubinstein, Jacek Capala, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Expert Review of Cardiovascular Therapy|September 22, 2011
Cardiac resynchronization therapy in mildly symptomatic heart failure: the earlier the betterSean Balmain, Michael A McDonald
Circulation|August 23, 2006
Angiotensin receptor blockers do not increase risk of myocardial infarctionRoss T Tsuyuki, Michael A McDonald
Academic Radiology|August 22, 2002
Multi-modal contrast agents: a first stepKenneth L Watkin, Michael A McDonald
Investigative Radiology|August 12, 2003
Small particulate gadolinium oxide and gadolinium oxide albumin microspheres as multimodal contrast and therapeutic agentsMichael A McDonald, Kenneth L Watkin
Current Opinion in Cardiology|March 12, 2009
Trying to succeed when the right ventricle failsMichael A McDonald, Heather J Ross
Advances in Applied Microbiology|October 22, 2018
Diversity-Function Relationships in Natural, Applied, and Engineered Microbial EcosystemsAndrew Free, Michael A McDonald, Eulyn Pagaling
Proceedings of Spie--The International Society for Optical Engineering|July 10, 2012
Protein Nanospheres: Synergistic Nanoplatform-Based Probes for Multimodality ImagingMichael A McDonald, Paul C Wang, Eliot L Siegel
The New England Journal of Medicine|January 15, 2010
Cardiac-resynchronization therapyJustin A Mariani, Michael A McDonald, Gary E Newton
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 24, 2012
Highly sensitized patients in cardiac transplantation: early outcomes from the Canadian Prioritized Organ Sharing ProgramSharon Chih, Heather J Ross, Michael A McDonald, et al.
Frontiers in Oncology|October 5, 2020
Phase 0 Radiopharmaceutical-Agent Clinical DevelopmentCharles A Kunos, Larry V Rubinstein, Jacek Capala, et al.
Pageof 5